Genetic Engineering 3
Aus der Reihe
Genetic Engineering: Principles and Methods
-
- Hardcover
- Taschenbuch ausgewählt
- eBook
-
Sprache:Englisch
-
Auflage:1982
- Softcover Reprint of the Original 1st 1988 edition Fr. 75.90
- Softcover Reprint of the Original 1st 1983 edition Fr. 75.90
- Softcover reprint of the original 1st ed. 1981 Fr. 72.90
- Softcover Reprint of the Original 1st 2000 edition Fr. 152.00
- Softcover reprint of the original 1st edition 2003 Fr. 138.00
- Softcover reprint of the original 1st edition 2002 Fr. 138.00
- Softcover reprint of the original 1st edition 2004 Fr. 138.00
- Softcover reprint of the original 1st ed. 1991 Fr. 72.90
- Softcover reprint of the original 1st ed. 2001 Fr. 138.00
- Softcover reprint of the original 1st ed. 1990 Fr. 137.00
- Softcover Reprint of the Original 1st 1997 edition Fr. 212.00
- Softcover Reprint of the Original 1st 1999 edition Fr. 152.00
- Softcover reprint of the original 1st ed. 1992 Fr. 72.90
- 1982 Fr. 72.90 ausgewählt
- Softcover reprint of the original 1st ed. 1979 Fr. 72.90
Fr. 72.90
inkl. gesetzl. MwSt.,
Beschreibung
Produktdetails
Einband
Taschenbuch
Erscheinungsdatum
10.05.2012
Abbildungen
XI, 173 p.
Verlag
Springer UsSeitenzahl
173
Maße (L/B/H)
23.5/15.5/1.1 cm
Gewicht
295 g
Auflage
1982
Sprache
Englisch
ISBN
978-1-4615-7080-6
Like many genetic engineers, I have recently been receiving the atten tion of various venture capital companies, international drug houses and Members of Parliament. I will not discuss which of these approaches are most welcome, but it did cause me to consider the speed of advance in genetic engineering, and the implications of this rapid growth. There were few who anticipated it - only five years ago, most scientists thought applications would come at the end of the century, yet we see products such as insulin and interferon already available for clinical testing. In Europe in general and Britain in particular, this explosive growth in our own field has coincided with a general industrial depression and a marked reduction in funding for biomedical research. The brain drain from Britain is a serious matter, for we are losing the best of our younger scientists, on whom we would rely to train the next generation of molecular biologists. These volumes have come from British labs (mostly because I happen to be based in London, and my contacts and friends are here), and I feel that the quality of the con tributions also shows that our current research is of a high standard.
Noch keine Bewertungen vorhanden
Verfassen Sie die erste Bewertung zu diesem Artikel
Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.